SEC filings
Biogen (BIIB)
Recent filings Biogen made with the SEC, newest first. Most have a short AI-generated summary, and every one links to the original.
CIK 0000875045All filings on SEC.gov
10-QQuarterly report
Quarterly report
Biogen completed its acquisition of Apellis on May 14, 2026, adding SYFOVRE for geographic atrophy and EMPAVELI for PNH, C3G, and primary IC-MPGN, and expects continued revenue declines for TECFIDERA and TYSABRI amid generic and biosimilar…
8-KCurrent report
Results of Operations and Financial Condition
Biogen reported third-quarter 2026 total revenue of $2.8 billion, up 11% year-over-year, with GAAP diluted EPS of $(0.14) and non-GAAP diluted EPS of $2.62, and raised the lower end of its full-year 2026 non-GAAP diluted EPS guidance to…
10-QQuarterly report
Quarterly report
Biogen completed its acquisition of Apellis on May 14, 2026, adding SYFOVRE for geographic atrophy and EMPAVELI for PNH, C3G and primary IC-MPGN. …
8-KCurrent report
Results of Operations and Financial Condition
Biogen Inc. reported strong financial results for the second quarter of 2026, achieving total revenue of $2.7 billion and seeing its growth portfolio generate $1.06 billion. …
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.
Follow Biogen in Readster
Add Biogen to your watchlist and its SEC filings reach your brief alongside the news about it, every line cited to its source. Readster also follows topics, people, newsletters and podcasts.
No credit card. When the trial ends, you move to Readster Free unless you subscribe.